Burden of rare variants in causative genes for amyotrophic lateral sclerosis (ALS) accelerates age at onset of ALS.


Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
05 2019
Historique:
received: 05 04 2018
revised: 30 07 2018
accepted: 26 09 2018
pubmed: 26 10 2018
medline: 20 3 2020
entrez: 26 10 2018
Statut: ppublish

Résumé

To evaluate the burden of rare variants in the causative genes for amyotrophic lateral sclerosis (ALS) on the age at onset of ALS in a Japanese case series. We conducted whole-exome sequencing analysis of 89 families with familial ALS (FALS) and 410 patients with sporadic ALS (SALS) to identify known pathogenic mutations or rare functionally predicted deleterious variants in the causative genes for ALS. Rare variants (minor allele frequency <1%) with scaled Combined Annotation-Dependent Depletion score >20 were defined as rare functionally predicted deleterious variants. The patients with ALS were classified on the basis of the number of pathogenic and/or rare functionally predicted deleterious variants, and the age at onset was compared among the classified groups. Whole-exome sequencing analysis revealed known pathogenic mutations or rare functionally predicted deleterious variants in causative genes for ALS in 56 families with FALS (62.9%) and 87 patients with SALS (21.2%). Such variants in multiple genes were identified in seven probands with FALS and eight patients with SALS. The ages at onset in the patients with ALS with multiple variants were significantly earlier than those in other patients with ALS. Even when the patients with known pathogenic mutations were excluded, a significantly earlier onset of the disease was still observed in patients with multiple rare functionally predicted deleterious variants. A substantial number of patients carried rare variants in multiple genes, and the burden of rare variants in the known causative genes for ALS affects the age at onset in the Japanese ALS series.

Identifiants

pubmed: 30355605
pii: jnnp-2018-318568
doi: 10.1136/jnnp-2018-318568
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

537-542

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Hiroya Naruse (H)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hiroyuki Ishiura (H)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Jun Mitsui (J)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yuji Takahashi (Y)

Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.

Takashi Matsukawa (T)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Masaki Tanaka (M)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Koichiro Doi (K)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Jun Yoshimura (J)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Shinichi Morishita (S)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Jun Goto (J)

Department of Neurology, International University of Health and Welfare Mita Hospital, Tokyo, Japan.

Tatsushi Toda (T)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Shoji Tsuji (S)

Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan tsuji@m.u-tokyo.ac.jp.
Institute of Medical Genomics, International University of Health and Welfare, Chiba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH